Wells Fargo analyst Timothy Daley initiated coverage of Repligen with an Overweight rating and $185 price target. The analyst recommends the shares based on the company’s “solid” acquisitions, R&D strategy, and competitive positioning in emerging therapies and biosimilars. It believes these will support “continued outsized earnings growth” and says fears of near-term headwinds are overblown.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGEN:
- Repligen to Report Second Quarter 2023 Financial Results
- RBC upgrades Repligen to Outperform as stock reaches ‘attractive entry point’
- Repligen assumed with an Overweight at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Repligen price target lowered to $200 from $210 at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue